Free Trial
→ The Trump Dump is starting; Get out of stocks now? (From Paradigm Press) (Ad) Buy MREO Stock  Free MREO Stock Alerts

Mereo BioPharma Group (MREO) Financials

Mereo BioPharma Group logo
$2.24 -0.04 (-1.75%)
Closing price 05/23/2025 04:00 PM Eastern
Extended Trading
$2.24 +0.00 (+0.22%)
As of 05/23/2025 07:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for Mereo BioPharma Group

Annual Income Statements for Mereo BioPharma Group

This table shows Mereo BioPharma Group's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016
Net Income / (Loss) Attributable to Common Shareholders		 -43 -29 -42 34 -447 -49 -42 -52 -35
Consolidated Net Income / (Loss)		 -43 -29 -42 17 -223 -46 -41 -52 -35
Net Income / (Loss) Continuing Operations		 -43 -29 -42 17 -223 -49 -42 -52 -35
Total Pre-Tax Income 		-43 -30 -43 17 -223 -54 -48 -63 -42
Total Operating Income		 -47 -28 -54 -30 -47 -52 -44 -61 -45
Total Gross Profit		 0.00 7.43 1.15 23 3.91 0.00 0.00 0.00 0.00
Total Revenue		 0.00 10 0.00 47 3.91 0.00 0.00 0.00 0.00
Operating Revenue		 0.00 10 0.00 47 3.91 0.00 - - -
Total Cost of Revenue		 0.00 2.57 -1.15 24 0.00 0.00 0.00 0.00 0.00
Operating Cost of Revenue		 0.00 2.57 -1.15 24 0.00 0.00 - - -
Total Operating Expenses		 47 36 56 53 51 52 44 61 45
Selling, General & Admin Expense		 26 18 26 22 29 21 15 14 14
Research & Development Expense		 21 17 29 32 22 31 29 47 30
Total Other Income / (Expense), net		 4.11 -1.57 11 47 -176 -4.65 -4.51 -2.22 3.03
Interest Expense		 1.37 2.88 4.18 - - 5.79 4.85 1.47 0.22
Interest & Investment Income		 3.04 2.13 0.84 - - 0.50 0.39 1.12 0.46
Other Income / (Expense), net		 2.44 -0.82 15 47 -176 0.64 -0.06 -1.87 2.79
Income Tax Expense		 0.00 -0.53 -0.72 - - -8.31 -6.72 -11 -6.58
Other Gains / (Losses), net		 0.00 -0.01 - - - - - - -
Basic Earnings per Share		 ($0.06) ($0.04) ($0.07) - - ($0.39) ($0.45) ($0.56) -
Weighted Average Basic Shares Outstanding		 739.62M 659.45M 603.20M 0.02 -0.48 97.96M 71.24M - -
Diluted Earnings per Share		 ($0.06) ($0.04) ($0.07) - - ($0.39) ($0.45) ($0.56) -
Weighted Average Diluted Shares Outstanding		 739.62M 659.45M 603.20M 584.91M 338.95M 97.96M 71.24M - -
Weighted Average Basic & Diluted Shares Outstanding		 795.00M 701.29M 624.93M 584.91M 338.95M 97.96M 71.24M - -

Quarterly Income Statements for Mereo BioPharma Group

This table shows Mereo BioPharma Group's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023
Period end date 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Net Income / (Loss) Attributable to Common Shareholders		 -7.05 -15 -12 -8.95 -11 -6.53 -1.75 -9.80
Consolidated Net Income / (Loss)		 -7.05 -15 -12 -8.95 -9.11 -6.53 -1.75 -12
Net Income / (Loss) Continuing Operations		 -7.05 -15 -12 -8.95 -9.12 -6.53 -1.75 -12
Total Pre-Tax Income 		-7.05 -15 -12 -8.95 -9.64 -6.53 -1.75 -12
Total Operating Income		 -15 -9.37 -13 -9.90 -7.13 -9.07 -0.81 -11
Total Operating Expenses		 15 9.37 13 9.90 8.06 9.30 6.38 12
Selling, General & Admin Expense		 6.46 6.20 7.87 5.91 3.60 5.71 2.67 6.45
Research & Development Expense		 8.82 3.17 4.95 3.99 4.81 3.59 3.71 5.31
Total Other Income / (Expense), net		 8.23 -5.63 0.56 0.95 -3.21 2.54 -0.94 0.04
Interest Expense		 0.38 0.35 0.33 0.31 0.35 0.70 1.03 0.80
Interest & Investment Income		 0.88 0.98 0.56 0.62 0.76 0.69 0.37 0.31
Other Income / (Expense), net		 7.73 -6.26 0.33 0.64 -3.62 2.55 -0.28 0.54
Basic Earnings per Share		 ($0.01) ($0.02) ($0.02) ($0.01) ($0.01) ($0.01) $0.00 ($0.02)
Weighted Average Basic Shares Outstanding		 739.62M 770.15M 711.77M 700.26M 659.45M 684.97M 628.42M 623.93M
Diluted Earnings per Share		 ($0.01) ($0.02) ($0.02) ($0.01) ($0.01) ($0.01) $0.00 ($0.02)
Weighted Average Diluted Shares Outstanding		 739.62M 770.15M 711.77M 700.26M 659.45M 684.97M 628.42M 623.93M
Weighted Average Basic & Diluted Shares Outstanding		 795.00M 775.73M 769.26M 701.36M 701.29M - - -

Annual Cash Flow Statements for Mereo BioPharma Group

This table details how cash moves in and out of Mereo BioPharma Group's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016
Net Change in Cash & Equivalents		 12 -11 -47 97 36 -11 -32 -2.90 48
Net Cash From Operating Activities		 -33 -21 -49 -8.17 2.18 -61 -29 -43 -37
Net Cash From Continuing Operating Activities		 -33 -21 -49 -8.17 2.18 -55 -28 -44 -35
Net Income / (Loss) Continuing Operations		 -43 -29 -42 0.00 0.00 -54 -48 -63 -42
Consolidated Net Income / (Loss)		 -43 -29 -42 - - -54 -48 -63 -42
Depreciation Expense		 0.14 0.17 0.18 - 2.18 2.09 0.05 0.05 0.04
Amortization Expense		 0.95 0.89 0.71 - - - - - -
Non-Cash Adjustments To Reconcile Net Income		 8.35 9.32 -9.48 -8.17 - 6.45 6.03 8.28 5.44
Changes in Operating Assets and Liabilities, net		 1.28 -2.05 1.99 - - -8.74 13 11 1.17
Net Cash From Investing Activities		 -0.70 -0.42 1.99 -0.72 0.00 57 0.32 -5.06 0.46
Net Cash From Continuing Investing Activities		 -0.70 -0.42 1.99 -0.72 0.00 44 0.32 -5.06 0.46
Acquisitions		 -0.70 -0.42 0.00 - - - - - -
Net Cash From Financing Activities		 46 7.97 0.20 106 34 -7.57 -2.64 46 84
Net Cash From Continuing Financing Activities		 46 7.97 0.20 106 34 -7.57 -2.05 46 84
Repayment of Debt		 0.00 -3.22 0.00 0.00 -27 -5.24 -2.10 -0.71 0.00
Repurchase of Common Equity		 -0.85 -0.51 0.00 - - -2.33 -0.40 -0.99 -3.70
Issuance of Common Equity		 47 12 0.20 - 0.00 0.00 0.35 20 84
Effect of Exchange Rate Changes		 -0.23 2.82 - - - - - - -
Cash Interest Paid		 0.02 0.88 0.02 0.00 3.96 - - - -
Cash Income Taxes Paid		 0.00 -1.34 1.88 - - - - - -

Quarterly Cash Flow Statements for Mereo BioPharma Group

This table details how cash moves in and out of Mereo BioPharma Group's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023
Period end date 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Net Change in Cash & Equivalents		 -11 -7.09 39 -8.69 -5.11 12 -7.69 -9.67
Net Cash From Operating Activities		 -9.42 -7.52 -7.90 -7.99 -6.79 2.66 -7.75 -9.25
Net Cash From Continuing Operating Activities		 -9.12 -7.52 -7.90 -7.99 -6.79 2.66 -7.75 -9.25
Net Income / (Loss) Continuing Operations		 -7.05 -15 -12 -8.95 -9.11 -6.53 -1.75 -12
Consolidated Net Income / (Loss)		 -7.05 -15 -12 -8.95 -9.11 -6.53 -1.75 -12
Depreciation Expense		 0.04 0.04 0.02 0.04 0.04 0.05 0.04 0.04
Amortization Expense		 0.24 0.24 0.23 0.23 0.24 0.24 0.23 0.19
Non-Cash Adjustments To Reconcile Net Income		 -3.78 8.35 2.22 1.56 4.83 1.43 1.33 1.73
Changes in Operating Assets and Liabilities, net		 1.43 -1.16 1.88 -0.87 -2.79 7.48 -7.60 0.87
Net Cash From Financing Activities		 -0.04 -0.59 47 0.00 - 7.91 0.07 0.00
Net Cash From Continuing Financing Activities		 -0.04 -0.59 47 0.00 - 7.91 0.07 0.00
Effect of Exchange Rate Changes		 -1.26 - - - 1.68 - - -
Cash Interest Paid		 0.01 - 0.01 0.00 0.02 0.00 0.18 0.68

Annual Balance Sheets for Mereo BioPharma Group

This table presents Mereo BioPharma Group's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018 2017
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017
Total Assets		 76 66 77 171 86 115 86 130
Total Current Assets		 75 64 75 134 41 40 44 85
Cash & Equivalents		 70 57 68 127 32 22 32 68
Prepaid Expenses		 2.18 5.16 5.45 3.78 2.21 2.80 1.36 2.66
Other Current Assets		 2.79 1.18 1.57 - - - - -
Plant, Property, & Equipment, net		 0.26 0.41 0.55 3.42 2.15 15 0.19 0.21
Total Noncurrent Assets		 1.37 2.33 1.67 33 43 59 42 45
Intangible Assets		 0.64 1.09 0.00 33 43 59 42 45
Other Noncurrent Operating Assets		 0.73 1.25 1.67 - - - - -
Total Liabilities & Shareholders' Equity		 76 66 77 165 86 107 86 130
Total Liabilities		 15 16 26 52 106 61 44 46
Total Current Liabilities		 14 9.49 24 17 12 40 21 13
Short-Term Debt		 5.54 0.00 13 0.00 - 20 8.71 2.62
Accounts Payable		 2.44 2.35 3.49 3.37 4.55 8.42 5.82 4.09
Accrued Expenses		 4.07 5.47 5.44 - 5.71 - 5.65 5.92
Other Current Liabilities		 1.80 1.67 2.12 6.34 1.44 3.84 0.42 0.37
Total Noncurrent Liabilities		 1.57 6.48 1.64 35 95 22 23 33
Long-Term Debt		 0.00 4.39 0.00 19 22 7.12 19 25
Other Noncurrent Operating Liabilities		 1.57 2.08 1.64 13 71 2.15 4.69 7.32
Commitments & Contingencies		 0.00 0.00 0.00 - - - - -
Total Equity & Noncontrolling Interests		 61 51 51 119 -20 53 42 84
Total Preferred & Common Equity		 61 51 51 119 -20 53 42 84
Total Common Equity		 61 51 51 -215 -241 -108 -109 -75
Common Stock		 543 489 479 2.37 1.39 0.39 0.27 0.29
Retained Earnings		 -463 -420 -405 -401 -423 -194 -142 -107
Treasury Stock		 0.00 -1.23 -1.34 -1.54 -1.78 -1.73 -0.39 0.00
Accumulated Other Comprehensive Income / (Loss)		 -19 -17 -22 - - - - -

Quarterly Balance Sheets for Mereo BioPharma Group

This table presents Mereo BioPharma Group's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2024 Q2 2024 Q1 2024
Period end date 9/30/2024 6/30/2024 3/31/2024
Total Assets		 89 96 56
Total Current Assets		 87 94 53
Cash & Equivalents		 81 87 49
Prepaid Expenses		 3.83 4.49 3.19
Other Current Assets		 2.37 2.02 1.65
Plant, Property, & Equipment, net		 0.32 0.34 0.36
Total Noncurrent Assets		 1.71 1.85 2.08
Intangible Assets		 0.80 0.87 0.97
Other Noncurrent Operating Assets		 0.91 0.99 1.11
Total Liabilities & Shareholders' Equity		 89 96 56
Total Liabilities		 16 17 13
Total Current Liabilities		 14 15 11
Short-Term Debt		 5.55 4.93 4.63
Accounts Payable		 1.75 2.70 2.46
Accrued Expenses		 3.53 3.72 2.54
Other Current Liabilities		 3.38 4.11 1.38
Total Noncurrent Liabilities		 2.00 2.01 2.10
Long-Term Debt		 0.00 0.00 0.00
Other Noncurrent Operating Liabilities		 2.00 2.01 2.10
Commitments & Contingencies		 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 73 79 43
Total Preferred & Common Equity		 73 79 43
Total Common Equity		 73 79 43
Common Stock		 539 538 490
Retained Earnings		 -456 -441 -429
Treasury Stock		 0.00 0.00 0.00
Accumulated Other Comprehensive Income / (Loss)		 -11 -18 -18

Annual Metrics And Ratios for Mereo BioPharma Group

This table displays calculated financial ratios and metrics derived from Mereo BioPharma Group's official financial filings.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016
Growth Metrics		 - - - - - - - - -
Revenue Growth		 -100.00% 0.00% -100.00% 1,105.41% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 -55.57% 27.22% -325.36% 107.76% -345.84% -12.98% 30.29% -50.74% 0.00%
EBIT Growth		 -53.65% 26.17% -330.53% 107.69% -332.05% -17.61% 30.27% -50.71% 0.00%
NOPAT Growth		 -66.68% 47.79% -25.70% 8.64% 9.49% -19.21% 28.23% -37.10% 0.00%
Net Income Growth		 -46.79% 30.21% -345.77% 107.69% -384.00% -13.15% 22.15% -49.63% 0.00%
EPS Growth		 -50.00% 42.86% 0.00% 0.00% 0.00% 13.33% 19.64% 0.00% 0.00%
Operating Cash Flow Growth		 -55.38% 56.72% -497.55% -474.13% 103.59% -106.46% 32.12% -18.66% 0.00%
Free Cash Flow Firm Growth		 -55.10% -28.82% 79.15% -204.66% 191.46% -247.80% 72.34% 0.00% 0.00%
Invested Capital Growth		 -32.45% 27.91% -118.72% 163.92% -136.79% 130.62% -17.91% 0.00% 0.00%
Revenue Q/Q Growth		 -100.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 6.80% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Q/Q Growth		 6.66% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
NOPAT Q/Q Growth		 -20.78% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Income Q/Q Growth		 4.55% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EPS Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth		 -8.71% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Invested Capital Q/Q Growth		 -35.44% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profitability Metrics		 - - - - - - - - -
Gross Margin		 0.00% 74.26% 0.00% 48.76% 100.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% -281.77% 0.00% 36.41% -5,653.49% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% -284.16% 0.00% -64.24% -1,210.85% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% -292.38% 0.00% 36.41% -5,709.28% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% -294.66% 0.00% 36.41% -5,709.28% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 98.23% 98.33% 100.00% 100.00% 84.74% 85.85% 82.64% 84.19%
Interest Burden Percent		 96.28% 102.60% 108.42% 100.00% 100.00% 105.34% 108.06% 100.56% 99.42%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% -133.73% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% -2,410.19% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% -1,224.89% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -77.58% -57.81% -49.61% 34.93% -1,358.62% -97.11% -64.69% -62.09% 0.00%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% -420.68% 0.00% -144.17% -61.78% -406.66% 0.00%
Operating Return on Assets (OROA)		 0.00% -40.63% 0.00% 13.39% -222.89% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% -40.95% 0.00% 13.39% -222.89% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -77.58% -57.81% 47.76% -162.19% 14,425.93% 221.71% 94.61% 55.40% 0.00%
Return on Equity Simple (ROE_SIMPLE)		 -70.94% -58.31% -82.14% 14.46% 1,092.97% -86.56% -97.74% -62.09% 0.00%
Net Operating Profit after Tax (NOPAT)		 -33 -20 -38 -30 -33 -37 -31 -43 -31
NOPAT Margin		 0.00% -198.91% 0.00% -64.24% -847.60% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -17.22% -17.75% -5.31% 87.31% 2,276.45% 109.22% -39.70% -44.58% 0.00%
Return On Investment Capital (ROIC_SIMPLE)		 -49.85% -36.21% - - - - - - -
Cost of Revenue to Revenue		 0.00% 25.74% 0.00% 51.24% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 184.24% 0.00% 45.59% 740.47% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 174.18% 0.00% 67.41% 570.38% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 358.42% 0.00% 113.00% 1,310.85% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -45 -29 -40 17 -223 -52 -44 -63 -42
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -44 -28 -39 17 -221 -50 -44 -63 -42
Valuation Ratios		 - - - - - - - - -
Price to Book Value (P/BV)		 8.91 5.71 1.71 0.00 0.00 0.00 0.00 0.00 0.00
Price to Tangible Book Value (P/TBV)		 9.00 5.84 1.71 0.00 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)		 0.00 28.87 0.00 2.30 17.92 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 3.16 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 31.68% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 18.26 0.00 2.88 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 23.57 0.00 7.14 72.22 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 19.62 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 19.62 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 129.44 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 3.81 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - -
Debt to Equity		 0.09 0.09 0.26 0.18 -1.16 0.74 0.66 0.33 0.00
Long-Term Debt to Equity		 0.00 0.09 0.00 0.18 -1.16 0.36 0.45 0.30 0.00
Financial Leverage		 -1.05 -1.06 -0.91 -1.11 0.51 0.18 -0.40 -0.51 0.00
Leverage Ratio		 1.28 1.41 1.46 2.61 6.10 2.11 1.71 1.54 0.00
Compound Leverage Factor		 1.23 1.45 1.58 2.61 6.10 2.22 1.85 1.55 0.00
Debt to Total Capital		 8.32% 8.00% 20.59% 15.50% 742.81% 42.56% 39.60% 24.93% 0.00%
Short-Term Debt to Total Capital		 8.32% 0.00% 20.59% 0.00% 0.00% 21.60% 12.60% 2.33% 0.00%
Long-Term Debt to Total Capital		 0.00% 8.00% 0.00% 15.50% 742.81% 20.96% 27.00% 22.60% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 237.62% 6,946.54% 173.62% 218.39% 142.04% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 91.68% 92.00% 79.41% -153.12% -7,589.35% -116.18% -157.99% -66.97% 0.00%
Debt to EBITDA		 -0.13 -0.16 -0.34 1.27 -0.11 -0.80 -0.62 -0.44 0.00
Net Debt to EBITDA		 1.47 1.88 1.42 -6.14 0.04 -0.36 0.18 0.68 0.00
Long-Term Debt to EBITDA		 0.00 -0.16 0.00 1.27 -0.11 -0.39 -0.42 -0.40 0.00
Debt to NOPAT		 -0.17 -0.22 -0.35 -0.72 -0.71 -1.08 -0.89 -0.65 0.00
Net Debt to NOPAT		 1.94 2.67 1.44 3.48 0.25 -0.49 0.25 1.00 0.00
Long-Term Debt to NOPAT		 0.00 -0.22 0.00 -0.72 -0.71 -0.53 -0.61 -0.59 0.00
Altman Z-Score		 11.66 1.70 -6.19 -0.60 -14.62 -3.39 0.00 0.00 0.00
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 196.28% 564.30% 1,161.81% 328.31% 246.25% 189.21% 0.00%
Liquidity Ratios		 - - - - - - - - -
Current Ratio		 5.40 6.72 3.09 7.92 3.47 1.02 2.13 6.57 0.00
Quick Ratio		 5.04 6.05 2.80 7.63 2.86 0.57 1.74 5.52 0.00
Cash Flow Metrics		 - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -32 -21 -16 -78 74 -81 -23 -84 0.00
Operating Cash Flow to CapEx		 0.00% 0.00% -375,546.15% -1,131.22% 0.00% -218,716.53% -68,056.39% -1,400.22% -1,294,153.94%
Free Cash Flow to Firm to Interest Expense		 -23.61 -7.24 -3.88 0.00 0.00 -14.00 -4.81 -57.25 0.00
Operating Cash Flow to Interest Expense		 -23.97 -7.34 -11.69 0.00 0.00 -10.51 -6.08 -29.49 -165.01
Operating Cash Flow Less CapEx to Interest Expense		 -23.97 -7.34 -11.70 0.00 0.00 -10.51 -6.09 -31.60 -165.02
Efficiency Ratios		 - - - - - - - - -
Asset Turnover		 0.00 0.14 0.00 0.37 0.04 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 28.57 3.65 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 20.92 0.00 16.96 0.45 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.88 0.00 6.10 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 12.78 100.04 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 413.92 0.00 59.83 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 -413.92 0.00 -47.05 100.04 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - -
Invested Capital		 -3.30 -2.49 -3.45 18 -29 78 34 41 0.00
Invested Capital Turnover		 0.00 -3.36 0.00 -9.06 0.16 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 -0.81 0.96 -22 47 -107 44 -7.43 41 0.00
Enterprise Value (EV)		 479 236 33 337 283 226 0.00 0.00 0.00
Market Capitalization		 543 289 88 108 70 47 0.00 0.00 0.00
Book Value per Share		 $0.08 $0.08 $0.09 ($0.64) ($2.46) ($1.51) ($1.53) $0.00 $0.00
Tangible Book Value per Share		 $0.08 $0.08 $0.09 ($0.73) ($2.91) ($2.34) ($2.12) $0.00 $0.00
Total Capital		 67 55 65 141 3.18 93 69 112 0.00
Total Debt		 5.54 4.39 13 22 24 40 27 28 0.00
Total Long-Term Debt		 0.00 4.39 0.00 22 24 19 19 25 0.00
Net Debt		 -64 -53 -55 -106 -8.43 18 -7.72 -43 0.00
Capital Expenditures (CapEx)		 0.00 0.00 0.01 0.72 0.00 0.03 0.04 3.10 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -3.35 -3.15 -4.03 -10 -3.15 -0.86 -3.04 3.99 0.00
Debt-free Net Working Capital (DFNWC)		 66 54 64 117 29 21 32 75 0.00
Net Working Capital (NWC)		 61 54 51 117 29 0.74 23 72 0.00
Net Nonoperating Expense (NNE)		 10 9.57 4.12 -47 190 9.52 10 9.57 3.78
Net Nonoperating Obligations (NNO)		 -64 -53 -55 -100 -8.43 25 -7.72 -43 0.00
Total Depreciation and Amortization (D&A)		 1.09 1.06 0.89 0.00 2.18 2.09 0.05 0.05 0.04
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% -31.47% 0.00% -21.50% -80.53% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 542.74% 0.00% 248.31% 738.35% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 542.74% 0.00% 248.31% 738.35% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.06) ($0.04) $0.00 $0.00 ($0.48) ($0.39) $0.00 $0.00 $0.00
Adjusted Weighted Average Basic Shares Outstanding		 739.62M 659.45M 0.00 0.00 338.95M 97.96M 71.24M 0.00 0.00
Adjusted Diluted Earnings per Share		 ($0.06) ($0.04) $0.00 $0.00 ($0.48) ($0.39) $0.00 $0.00 $0.00
Adjusted Weighted Average Diluted Shares Outstanding		 739.62M 659.45M 624.93M 584.91M 338.95M 97.96M 71.24M 0.00 0.00
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 ($0.48) ($0.39) $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 795.00M 701.29M 624.93M 584.91M 338.95M 97.96M 71.24M 0.00 0.00
Normalized Net Operating Profit after Tax (NOPAT)		 -33 -20 -38 -21 -33 -37 -31 -43 -31
Normalized NOPAT Margin		 0.00% -198.91% 0.00% -44.97% -847.60% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% -299.98% 0.00% 36.41% -5,709.28% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - -
EBIT to Interest Expense		 -32.79 -10.15 -9.49 0.00 0.00 -8.93 -9.07 -42.83 -188.67
NOPAT to Interest Expense		 -24.20 -6.90 -9.13 0.00 0.00 -6.33 -6.34 -29.09 -140.88
EBIT Less CapEx to Interest Expense		 -32.79 -10.15 -9.49 0.00 0.00 -8.94 -9.08 -44.94 -188.69
NOPAT Less CapEx to Interest Expense		 -24.20 -6.90 -9.13 0.00 0.00 -6.33 -6.35 -31.20 -140.89
Payout Ratios		 - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 -1.97% -1.73% 0.00% 0.00% 0.00% -5.05% -0.98% -1.88% -10.55%

Quarterly Metrics And Ratios for Mereo BioPharma Group

This table displays calculated financial ratios and metrics derived from Mereo BioPharma Group's official financial filings.

Metric Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023
Period end date 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Growth Metrics		 - - - - - - - -
Revenue Growth		 0.00% 0.00% -100.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 30.47% -146.06% -1,383.74% 15.63% 0.00% 0.00% 0.00% 0.00%
EBIT Growth		 29.74% -139.74% -1,040.00% 14.86% 0.00% 0.00% 0.00% 0.00%
NOPAT Growth		 -114.32% -3.37% -1,480.02% 13.23% 0.00% 0.00% 0.00% 0.00%
Net Income Growth		 22.64% -129.69% -599.89% 25.88% 0.00% 0.00% 0.00% 0.00%
EPS Growth		 0.00% -100.00% 0.00% 50.00% 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Growth		 -38.75% -382.78% -1.93% 13.59% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow Firm Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Invested Capital Growth		 -32.45% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% -100.00% 0.00% 0.00%
EBITDA Q/Q Growth		 52.58% -25.54% -36.10% 0.00% -67.81% -657.04% 92.26% 0.00%
EBIT Q/Q Growth		 51.69% -25.22% -34.83% 0.00% -64.86% -495.43% 89.93% 0.00%
NOPAT Q/Q Growth		 -62.99% 26.85% -29.43% 0.00% 21.39% -1,018.00% 92.89% 0.00%
Net Income Q/Q Growth		 53.03% -22.41% -36.91% 0.00% -39.46% -272.99% 85.50% 0.00%
EPS Q/Q Growth		 50.00% 0.00% -100.00% 0.00% 0.00% 0.00% 100.00% 0.00%
Operating Cash Flow Q/Q Growth		 -25.28% 4.87% 1.09% 0.00% -355.32% 134.29% 16.15% 0.00%
Free Cash Flow Firm Q/Q Growth		 -139.59% 19.41% 10.77% 0.00% 0.00% 0.00% 0.00% 0.00%
Invested Capital Q/Q Growth		 -35.44% 36.75% -222.99% 0.00% 0.00% 0.00% 0.00% 0.00%
Profitability Metrics		 - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 162.10% 0.00% 61.89% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% -1,046.80% 0.00% -9.16% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% -712.80% 0.00% -9.01% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% -1,074.90% 0.00% -12.17% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% -910.80% 0.00% -19.46% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 94.48% 100.00% 100.00% 100.00%
Interest Burden Percent		 93.30% 95.97% 98.17% 96.68% 89.68% 100.17% 159.91% 111.05%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -77.58% -62.47% -46.85% -61.49% -57.81% 0.00% 0.00% 0.00%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% -149.38% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% -126.58% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -77.58% -62.47% -46.85% -61.49% -57.81% 0.00% 0.00% 0.00%
Return on Equity Simple (ROE_SIMPLE)		 0.00% -62.47% -46.85% -61.49% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -11 -6.56 -8.97 -6.93 -4.99 -6.35 -0.57 -7.99
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% -498.96% 0.00% -6.31% 0.00%
Net Nonoperating Expense Percent (NNEP)		 6.22% -22.52% -7.96% -9.18% -7.77% 0.00% 0.00% 0.00%
Return On Investment Capital (ROIC_SIMPLE)		 -16.08% - - - -9.08% - - -
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% -62.10% 0.00% 38.11% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 359.70% 0.00% 29.66% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 480.50% 0.00% 41.24% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 805.50% 0.00% 70.90% 0.00%
Earnings before Interest and Taxes (EBIT)		 -7.55 -16 -12 -9.26 -11 -6.52 -1.10 -11
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -7.28 -15 -12 -8.98 -10 -6.24 -0.82 -11
Valuation Ratios		 - - - - - - - -
Price to Book Value (P/BV)		 8.91 8.72 6.42 10.80 5.71 0.00 0.00 0.00
Price to Tangible Book Value (P/TBV)		 9.00 8.81 6.49 11.06 5.84 0.00 0.00 0.00
Price to Revenue (P/Rev)		 0.00 632.33 504.98 46.28 28.87 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 557.36 422.48 41.88 23.57 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - -
Debt to Equity		 0.09 0.08 0.06 0.11 0.09 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.09 0.00 0.00 0.00
Financial Leverage		 -1.05 -1.03 -1.05 -1.03 -1.05 0.00 0.00 0.00
Leverage Ratio		 1.28 1.22 1.22 1.31 1.41 0.00 0.00 0.00
Compound Leverage Factor		 1.20 1.17 1.20 1.26 1.27 0.00 0.00 0.00
Debt to Total Capital		 8.32% 7.11% 5.90% 9.75% 8.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 8.32% 7.11% 5.90% 9.75% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 8.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 91.68% 92.89% 94.10% 90.25% 92.00% 0.00% 0.00% 0.00%
Debt to EBITDA		 -0.13 -0.12 -0.13 -0.17 -0.16 0.00 0.00 0.00
Net Debt to EBITDA		 1.47 1.59 2.18 1.66 1.88 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 -0.16 0.00 0.00 0.00
Debt to NOPAT		 -0.17 -0.20 -0.18 -0.25 -0.22 0.00 0.00 0.00
Net Debt to NOPAT		 1.94 2.73 3.03 2.34 2.67 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 -0.22 0.00 0.00 0.00
Altman Z-Score		 13.27 16.62 11.48 11.02 2.61 0.00 0.00 0.00
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - -
Current Ratio		 5.40 6.10 6.07 4.86 6.72 0.00 0.00 0.00
Quick Ratio		 5.04 5.67 5.65 4.42 6.05 0.00 0.00 0.00
Cash Flow Metrics		 - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -9.89 -4.13 -5.12 -5.74 0.00 0.00 0.00 0.00
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 -26.29 -11.69 -15.47 -18.51 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 -25.05 -21.30 -23.88 -25.78 -19.29 3.80 -7.54 -11.56
Operating Cash Flow Less CapEx to Interest Expense		 -25.05 -21.30 -23.88 -25.78 -19.29 3.80 -7.54 -11.56
Efficiency Ratios		 - - - - - - - -
Asset Turnover		 0.00 0.01 0.01 0.18 0.14 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 3.17 2.96 27.78 20.92 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 1.05 0.88 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 348.13 413.92 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 -348.13 -413.92 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - -
Invested Capital		 -3.30 -2.44 -3.85 -1.19 -2.49 0.00 0.00 0.00
Invested Capital Turnover		 0.00 -0.82 -0.52 -16.78 -4.02 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 -0.81 -2.44 -3.85 -1.19 0.00 0.00 0.00 0.00
Enterprise Value (EV)		 479 557 422 419 236 0.00 0.00 0.00
Market Capitalization		 543 632 505 463 289 161 165 88
Book Value per Share		 $0.08 $0.09 $0.11 $0.06 $0.08 $0.00 $0.00 $0.00
Tangible Book Value per Share		 $0.08 $0.09 $0.11 $0.06 $0.08 $0.00 $0.00 $0.00
Total Capital		 67 78 84 47 55 0.00 0.00 0.00
Total Debt		 5.54 5.55 4.93 4.63 4.39 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 4.39 0.00 0.00 0.00
Net Debt		 -64 -75 -83 -44 -53 0.00 0.00 0.00
Capital Expenditures (CapEx)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -3.35 -2.46 -4.03 -1.54 -3.15 0.00 0.00 0.00
Debt-free Net Working Capital (DFNWC)		 66 78 83 47 54 0.00 0.00 0.00
Net Working Capital (NWC)		 61 73 78 42 54 0.00 0.00 0.00
Net Nonoperating Expense (NNE)		 -3.65 8.44 3.29 2.02 4.12 0.18 1.18 4.09
Net Nonoperating Obligations (NNO)		 -64 -75 -83 -44 -53 0.00 0.00 0.00
Total Depreciation and Amortization (D&A)		 0.27 0.28 0.26 0.28 0.28 0.28 0.27 0.23
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% -245.60% -402.60% -15.38% -31.47% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 7,806.60% 8,340.50% 471.22% 542.74% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 7,251.50% 7,847.40% 424.92% 542.74% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.01) ($0.02) ($0.02) ($0.01) ($0.01) $0.00 $0.00 $0.00
Adjusted Weighted Average Basic Shares Outstanding		 739.62M 770.15M 711.77M 700.26M 659.45M 0.00 0.00 0.00
Adjusted Diluted Earnings per Share		 ($0.01) ($0.02) ($0.02) ($0.01) ($0.01) $0.00 $0.00 $0.00
Adjusted Weighted Average Diluted Shares Outstanding		 739.62M 770.15M 711.77M 700.26M 659.45M 0.00 0.00 0.00
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 795.00M 775.73M 769.26M 701.36M 701.29M 0.00 0.00 0.00
Normalized Net Operating Profit after Tax (NOPAT)		 -11 -6.56 -8.97 -6.93 -4.99 -6.35 -0.57 -7.99
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% -498.96% 0.00% -6.31% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% -964.00% 0.00% -19.46% 0.00%
Debt Service Ratios		 - - - - - - - -
EBIT to Interest Expense		 -20.09 -44.28 -37.71 -29.86 -30.54 -9.31 -1.06 -13.59
NOPAT to Interest Expense		 -28.44 -18.59 -27.10 -22.35 -14.18 -9.07 -0.55 -9.98
EBIT Less CapEx to Interest Expense		 -20.09 -44.28 -37.71 -29.86 -30.54 -9.31 -1.06 -13.59
NOPAT Less CapEx to Interest Expense		 -28.44 -18.59 -27.10 -22.35 -14.18 -9.07 -0.55 -9.98
Payout Ratios		 - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 -1.97% 0.00% 0.00% 0.00% -1.73% 0.00% 0.00% 0.00%

Frequently Asked Questions About Mereo BioPharma Group's Financials

When does Mereo BioPharma Group's financial year end?

According to the most recent income statement we have on file, Mereo BioPharma Group's fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Mereo BioPharma Group's net income changed over the last 8 years?

Mereo BioPharma Group's net income appears to be on a downward trend, with a most recent value of -$43.25 million in 2024, rising from -$35.03 million in 2016. The previous period was -$29.47 million in 2023. Check out Mereo BioPharma Group's forecast to explore projected trends and price targets.

What is Mereo BioPharma Group's operating income?
Mereo BioPharma Group's total operating income in 2024 was -$47.36 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $47.36 million
How has Mereo BioPharma Group revenue changed over the last 8 years?

Over the last 8 years, Mereo BioPharma Group's total revenue changed from $0.00 in 2016 to $0.00 in 2024, a change of 0.0%.

How much debt does Mereo BioPharma Group have?

Mereo BioPharma Group's total liabilities were at $15.42 million at the end of 2024, a 3.4% decrease from 2023, and a 66.3% decrease since 2017.

How much cash does Mereo BioPharma Group have?

In the past 7 years, Mereo BioPharma Group's cash and equivalents has ranged from $21.66 million in 2019 to $127.30 million in 2021, and is currently $69.80 million as of their latest financial filing in 2024.

How has Mereo BioPharma Group's book value per share changed over the last 8 years?

Over the last 8 years, Mereo BioPharma Group's book value per share changed from 0.00 in 2016 to 0.08 in 2024, a change of 7.9%.


Related Companies

This page (NASDAQ:MREO) was last updated on 5/25/2025 by MarketBeat.com Staff
From Our Partners
White House to reset Social Security?
Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...
Altimetry | Sponsored
A grave, grave error.
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...
Porter & Company | Sponsored
This Signal Only Flashes Once Every 4 Years – And It Just Triggered
This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...
Crypto Swap Profits | Sponsored
Collect $7k per month from Tesla’s SECRET dividend
Tesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...
Investors Alley | Sponsored
Why Elon put $51 million into this
Why Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT Scientists
True Market Insiders | Sponsored
Elon’s NEXT Big IPO?
Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...
Banyan Hill Publishing | Sponsored
The one deadline Elon can't afford to miss...
For years, Elon Musk made headlines for blowing past deadlines — so often that investors coined a nickname for...
Brownstone Research | Sponsored
3..2..1.. AI 2.0 ignition (don’t sleep on this)
I just put together an urgent new presentation that you need to see right away. In short: I believe we are...
Timothy Sykes | Sponsored